SCHEMBL20048709

SCHEMBL20048709

CC(C)c1ccc(N(c2ccc(C(C)C)cc2)c2ccc3ccccc3c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGT2B7 P16662 1/20 0.50
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP1A2 P05177 2/20 0.40
AOC3 Q16853 2/20 0.40
CYP2D6 P10635 1/20 0.40
TSHR P16473 1/20 0.40
HIF1A Q16665 1/20 0.40
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
ATM Q13315 1/20 0.40
CYP2A6 P11509 3/20 0.39
TDP1 Q9NUW8 1/20 0.39
MMP9 P14780 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13338860 1.00 UGT2B7 (0.50) UGT2B7MEN1KMT2ACYP1A2AOC3
SCHEMBL13338861 0.96 UGT2B7 (0.47) UGT2B7MEN1KMT2ACYP1A2AOC3
SCHEMBL16344274 0.95 UGT2B7 (0.46) UGT2B7MEN1KMT2ACYP1A2AOC3
SCHEMBL13339006 0.95 UGT2B7 (0.46) UGT2B7MEN1KMT2ACYP1A2AOC3
SCHEMBL21348038 0.93 HTT (0.48) UGT2B7MEN1KMT2ACYP1A2AOC3
SCHEMBL15002694 0.93 UGT2B7 (0.44) UGT2B7MEN1KMT2ACYP1A2AOC3
SCHEMBL13338904 0.92 UGT2B7 (0.55) UGT2B7MEN1KMT2ACYP1A2AOC3
SCHEMBL13339016 0.92 UGT2B7 (0.43) UGT2B7CYP1A2CYP2D6TDP1L3MBTL1
SCHEMBL13338910 0.91 UGT2B7 (0.50) UGT2B7MEN1KMT2ACYP1A2AOC3
SCHEMBL12292308 0.90 RELA (0.47) UGT2B7MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11316118-B2 Dibenzo[d,B]silole-based reactive mesogens LOMOX LIMITED (GB) 2022-04-26 US disclosed
EP-3523313-B1 DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS LOMOX LTD (GB) 2021-05-05 EP disclosed
US-20190280223-A1 DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS LOMOX LIMITED (GB) 2019-09-12 US disclosed
WO-2018065786-A1 DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS LOMOX LIMITED (GB) 2018-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190280223-A1 DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS CCNB1, CCNE2, UBE2G2 UGT2B7 516/4885MEN1 780/4885KMT2A 867/4885
US-11316118-B2 Dibenzo[d,B]silole-based reactive mesogens CCNB1, CCNE2, UBE2G2 UGT2B7 516/4885MEN1 780/4885KMT2A 867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.